La vendita allo scoperto per Matinas BioPharma Hldgs dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Matinas BioPharma Hldgs. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Matinas BioPharma Hldgs (AMEX:MTNB) Azioni, Report sulle vendite allo scoperto

Matinas BioPharma Hldgs

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Holdings Inc

JMP Securities analyst Nicholas Jones maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Market Outperform and raises the price target from $265 to $285.

News

Price Target

Analyst Ratings

AMZN

JMP Securities Maintains Market Outperform on Amazon.com, Raises Price Target to $285

Piper Sandler analyst Christopher Raymond maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $1242 to $1195.

REGN

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1195

Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) — the parent company of KFC, Pizza Hut, and Taco Bell — will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/YUMC/earnings">opening bell on Monday, Nov. 4.</a>
Analysts expect the China-based company to report quarterly earnings at 67 cents per share, up from 59 cents per share in the year-ago period. Yum China projects to report revenue of $3.05 billion for the recent quarter, compared to $2.91 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Aug. 5, Yum China reported second-quarter results yesterday. Revenue increased 1% year over year to $2.68 billion, missing the consensus of $2.77 billion.
With the recent buzz around Yum China, some investors may be eyeing potential gains from the company's dividends too. As of now, Yum China offers an annual dividend yield of 1.45%, which is a quarterly dividend amount of 16 cents per share (64 cents a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $413,531 or around 9,375 shares. For a more modest $100 per month or $1,200 per year, you would need $82,706 or around 1,875 shares.
To Calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend (64 cents in this case). So, $6,000 / $0.64 = 9,375 ($500 per month), and $1,200 / $0.64 = 1,875 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How That Works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
Price Action: Shares of Yum China fell 1.3% to close at $44.11 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41654255/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-8-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields</a></li>
</ul>
Image: Unsplash

Earnings

Long Ideas

Markets

Trading Ideas

YUMC

How To Earn $500 A Month From Yum China Stock Ahead Of Q3 Earnings

Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) reported quarterly earnings of C$2.33 per share which beat the analyst consensus estimate of C$2.00 by 16.5 percent. This is a 15.58 percent decrease over earnings of C$2.76 per share from the same period last year. The company reported quarterly sales of C$13.259 billion which missed the analyst consensus estimate of C$15.636 billion by 15.20 percent. This is a 4.75 percent decrease over sales of C$13.920 billion the same period last year.

Earnings Beats

Earnings Misses

Imperial Oil Q3 2024 GAAP EPS C$2.33 Beats C$2.00 Estimate, Sales C$13.259B Miss C$15.636B Estimate

DA Davidson analyst Linda Bolton Weiser maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and lowers the price target from $130 to $81.

DA Davidson Maintains Buy on Estee Lauder Cos, Lowers Price Target to $81

2024 Guidance The Company currently estimates net income to be within a range of $7.18 to $7.28 per diluted share and FFO to be within a range of $12.80 to $12.90 per diluted share, excluding the $0.14 per diluted share of unrealized losses in fair value adjustments of the Klépierre exchangeable bonds and publicly traded equity instruments, net for the year ending December 31, 2024.&nbsp; &nbsp;&nbsp;
The following table provides the GAAP to non-GAAP reconciliation for the expected range of estimated net income attributable to common stockholders per diluted share to FFO per diluted share:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">For the year ending December 31, 2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">End</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">End</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Estimated net income attributable to common stockholders</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">per diluted share</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$7.18</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$7.28</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and amortization including Simon's share</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">of unconsolidated entities</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">5.50</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">5.50</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gain on acquisition of controlling interest, sale or</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">disposal of, or recovery on, assets and interest in</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">unconsolidated entities and impairment, net</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(0.02)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(0.02)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Estimated FFO per diluted share</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.66</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.76</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Unrealized losses in fair value adjustments</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">of the Klépierre exchangeable bonds and</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">publicly traded equity instruments, net</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">0.14</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">0.14</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Estimated FFO per diluted share, excluding unrealized</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">losses in fair value adjustments of the</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Klépierre exchangeable bonds and</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">publicly traded equity instruments, net</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.80</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$12.90</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Guidance

Simon Property Group Sees FY24 EPS $7.18-$7.28 Vs $7.12 Est.; FFO $12.80-$12.90

Piper Sandler analyst Thomas Champion maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Overweight and raises the price target from $54 to $65.

RBLX

Piper Sandler Maintains Overweight on Roblox, Raises Price Target to $65

TOVX: 67% &#x7C; <a href="https://www.benzinga.com//node/41665409">Theriva Biologics shares are trading higher after the company announced it was selected as a finalist for Merck KGaA's EMEA Advance Biotech Grant.</a>
&nbsp;
TEAM: 21% &#x7C; <a href="https://www.benzinga.com//node/41680189">Atlassian shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 revenue guidance above estimates.</a>
&nbsp;
EOSE: 14% &#x7C; <a href="https://www.benzinga.com//node/41680096">Eos Energy Enterprises shares are trading higher after the company announced it achieved its second set of performance milestones where achieving these results enables an additional $65 million from the delayed draw term loan.</a>

Movers

EOSE

TEAM

TOVX

Market-Moving News for November 1st

U.S.-listed Chinese EV startups Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), and XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) reported their October delivery numbers on Friday with Li Auto topping the three by a significant margin.
Li Auto Tops The Chart: Li Auto said on Friday that it delivered 51,443 vehicles in October, marking a 27.3% jump in sales year-over-year but a 4% drop from September when it delivered nearly 54,000 vehicles.
The rise in sales, <a href="https://www.benzinga.com/news/earnings/24/10/41647868/li-auto-q3-earnings-24-topline-growth-1-million-deliveries-milestone-q4-revenue-outlook-lags-street">Li Auto said</a>, could be attributed to robust sales across its model lineup. The company also crossed the landmark of delivering over 1 million vehicles cumulatively in October. 
XPeng Mona M03 Deliveries Exceed 10k Units: XPeng&nbsp;also witnessed its deliveries rise in October but couldn't keep up with Li Auto's pace. The company delivered 23,917 vehicles last month, marking an increase of 20% year-over-year and 12% from September.
The Guangzhou-based EV startup said that the company&#8217;s deliveries of the <a href="https://www.benzinga.com/markets/equities/24/07/39618570/xpeng-debuts-mona-series-with-m03-with-official-launch-in-august-report">XPENG MONA M03 </a>hatchback coupe alone exceeded 10,000 units. 
ONVO Spurs Nio Forward: Shanghai-based Nio, meanwhile, delivered 20,976 vehicles in October, including 16,657 NIO brand vehicles and 4,319 <a href="https://www.benzinga.com/markets/equities/24/10/41195060/tesla-rival-nio-accelerates-global-expansion-to-launch-evs-in-middle-east-amid-eu-tariff-concern">ONVO brand vehicles</a>. This marks a near 1% dip from its September delivery numbers and a whopping 30.5% rise from its sales in October 2023.
Deliveries of the first ONVO vehicle &#8211; the ONVO L60 &#8211; commenced in late September, making October the first whole month of sales for the family-oriented EV brand.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41647639/teslas-chinese-rival-byd-outshines-elon-musks-ev-giant-in-quarterly-revenue-for-first-time-since-202" target="_blank" rel="noreferrer noopener">Chinese EV Behemoth BYD Tops Tesla's Revenue For First Time Since 2022 In Q3</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

XPEV

Li Auto Leads The Pack, XPeng, Nio Clock Growth: Here's How October Deliveries Of Chinese EV Startups Stack Up

HSBC analyst Meredith Jensen downgrades Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) from Buy to Hold and announces $156 price target.

Downgrades

HSBC Downgrades Hyatt Hotels to Hold, Announces $156 Price Target

Michael Saylor&#8216;s declaration that &#8220;MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is the public equity play on Bitcoin maximalism&#8221; aptly defines the company&#8217;s pioneering approach in <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41585530/asias-microstrategy-metaplanet-buys-another-10-4m-in-bitcoin-exceeds-1-000-btc-holdings">corporate Bitcoin holdings</a>.
Saylor highlighted the company&#8217;s strategy in a post on X on Thursday:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">MicroStrategy is the public equity play on <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> Maximalism. <a href="https://t.co/96lpcdN5Zi">pic.twitter.com/96lpcdN5Zi</a>
&mdash; Michael Saylor&#x26a1;&#xFE0F; (@saylor) <a href="https://twitter.com/saylor/status/1852116357724475532?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
How MicroStrategy Leverages Bitcoin: MicroStrategy has not only redefined its own treasury strategy but also set a model that other companies are now beginning to emulate.
The firm's Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)-centric approach, producing returns well above the S&amp;P 500, has led to notable shifts in corporate treasury strategies worldwide.
Since MicroStrategy's pivot in 2020, the company has consistently purchased Bitcoin, achieving an annual average return of 44%, significantly higher than the S&amp;P 500&#8217;s 12% <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40776328/microstrategys-bitcoin-strategy-has-outperformed-every-s-p-500-company-and-even-nvidia-sin">during the same period</a>, Saylor told CNBC in a recent interview.
Notably, MicroStrategy's strategy yielded an 825% return, outperforming even Nvidia&#8217;s 821% rise, further showcasing the power of its Bitcoin holdings. 
The firm continues its role as a &#8220;cash cow&#8221; in the software sector while embracing Bitcoin as a primary treasury asset, according to Saylor. 
This dual model allows MicroStrategy to finance Bitcoin acquisitions through securitized instruments like convertible bonds, presenting investors with exposure to Bitcoin at a reduced volatility level.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41667204/what-coin-should-i-buy-binance-founder-changpeng-zhao-shares-anecdotes-from-4-month-prison">&#8216;What Coin Should I Buy?&#8217;—Binance Founder Changpeng Zhao Shares Anecdotes From 4-Month Prison Stint</a>
Who&#8217;s Following The MicroStrategy Apporach: The bold move has stirred interest among other companies, especially as MicroStrategy recently announced its acquisition of 25,889 BTC in Q3, valued at $1.6 billion.
The strategy brought the company's total holdings to 252,220 BTC, worth approximately $18.23 billion, positioning it as a prominent advocate for using Bitcoin as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41646462/michael-saylor-says-bitcoin-remedy-to-fix-unhealthy-balance-sheets-as-microstrategy-unveil">hedge in uncertain economic times.</a> 
Despite the risks associated with Bitcoin's volatility, Saylor emphasized that Bitcoin "fixes the balance sheet," offering liquidity and resilience to a firm's finances. 
MicroStrategy plans to raise an additional $42 billion through equity and debt financing in the coming years to further its Bitcoin acquisitions, reinforcing its belief in Bitcoin's long-term value.
Following MicroStrategy's example, companies like Cathedra Bitcoin (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBTTF#OTC">CBTTF</a>), Metaplanet and Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) have implemented similar Bitcoin-centered approaches.
Cathedra Bitcoin, listed on the TSX Venture Exchange, has transitioned its operations from mining to data management to sustainably increase its Bitcoin holdings. 
Meanwhile, Metaplanet has prioritized Bitcoin growth month-over-month, achieving a 587% stock increase this year, reflecting a shift toward maximizing Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40942247/microstrategys-bitcoin-playbook-is-becoming-a-hit-among-companies-but-theres-a-catch">reserves to enhance shareholder value.</a>
This shift, coined the &#8220;<a href="https://www.benzinga.com/startups/24/10/41434521/tesla-quietly-transfers-765-million-in-bitcoin-putting-musks-cryptocurrency-strategy-under-intense-s">maximize Bitcoin per share</a>&#8221; approach, is becoming a compelling alternative for firms seeking inflation hedges and asset stability.
For those interested in the ongoing impact of this strategy on the digital finance landscape, Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 will be a pivotal platform to explore further, with discussions on corporate adoption and innovations in digital assets expected.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41662414/donald-trump-wishes-bitcoiners-happy-birthday-vows-to-end-kamalas-war-on-crypto-as-world-l">Donald Trump Wishes Bitcoiners &#8216;Happy Birthday&#8217;, Vows To &#8216;End Kamala&#8217;s War On Crypto&#8217; As World Liberty Financial Falls Way Short Of Fundraising Goal</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

CBTTF

MSTR

SMLR

Michael Saylor Calls MicroStrategy The 'Public Equity Play On Bitcoin Maximalism': Here's Who's Following This Approach

Dividends
Today, Simon&#39;s Board of Directors declared a quarterly common stock dividend of $2.10 for the fourth quarter of 2024. &nbsp;This is an increase of $0.20, or 10.5% year-over-year.&nbsp; The dividend will be payable on December 30, 2024 to shareholders of record on December 9, 2024.&nbsp;
Simon&#39;s Board of Directors declared the quarterly dividend on its 8 3/8% Series J Cumulative Redeemable Preferred Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGPRJ#NYSE">SPGPRJ</a>) of $1.046875 per share, payable on December 30, 2024 to shareholders of record on December 16, 2024.&nbsp;

Dividends

SPGPRJ

Simon Property Group Increases Quarterly Dividend From $2.05 To $2.10 Per Share

Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.39 by 10.26 percent. This is a 21.82 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $88.81 million which beat the analyst consensus estimate of $83.92 million by 5.82 percent. This is a 17.23 percent decrease over sales of $107.29 million the same period last year.

Arbor Realty Trust Q3 2024 Adj EPS $0.43 Beats $0.39 Estimate, Sales $88.81M Beat $83.92M Estimate

Brings Extensive Deal-Making And Strategic Experience, Including $700M Licensing Deal With Dr. Reddy's Lab; Highlights Potential Benefits Of Low-Dose Interleukin-2 In Alzheimer's Phase 2 Trial

Management

COYA

Coya Therapeutics Appoints Arun Swaminathan, Ph.D., As CEO

Contracts

CLSK

Canaan To Provide CleanSpark With 3800 Avalon A1566I Immersion Cooling Miners; Financial Details Not Disclosed

Biotech

General

Novo Nordisk's Semaglutide 2.4 mg Achieves Primary Endpoints In Essence Trial, Showing Significant Improvement In Liver Fibrosis And MASH Resolution At Week 72 With Positive Safety Profile; Regulatory Filings Planned For U.S. And EU In 1H 2025, With Detailed Results To Be Presented This Year And Part 2 Readout Expected In 2029

TD Cowen analyst John Blackledge maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $230 to $240.

TD Cowen Maintains Buy on Amazon.com, Raises Price Target to $240

Financing

FCEL

FuelCell Energy Closes On Project Debt Financing Transaction With EXIM For Gyeonggi Green Energy Projects; Co. To Receive ~$9.4M In Debt Financing

Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $300 price target.

ALNY

Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $300 Price Target

WIIM

BFLY

Butterfly Network shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.

Matinas Biopharma Q2 2024 Earnings Preview

Matinas Biopharma GAAP EPS of -$0.02 beats by $0.01

Matinas BioPharma Holdings, Inc. 2024 Q2 - Results - Earnings Call Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Matinas BioPharma Hldgs (NYSEMKT:<a href="https://investorplace.com/stock-quotes/mtnb-stock-quote/">MTNB</a>) just reported results for the second quarter of 2024.<ul><li>Matinas BioPharma Hldgs reported earnings per share of -2 cents. This met the analyst estimate for EPS of -2 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mtnb-stock-earnings-matinas-biopharma-hldgs-for-q2-of-2024/">MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024

Matinas BioPharma (MTNB) has provided an update. The Company has updated its corporate presentation for use at upcoming conferences and investor me...

Matinas BioPharma Releases Updated Corporate Presentation

Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price...

Buy Rating Affirmed: Matinas BioPharma's Solid Financials and Promising Drug Development

These are the upcoming stock splits for the week of September 2 to September 6, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a c...

Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested

Maxim downgraded Matinas BioPharma (MTNB) to Hold from Buy. The company announced that partnering negotiations for its lead asset MAT2203 – oral am...

Matinas BioPharma cut to Hold at Maxim on termination of MAT2203 talks

Matinas BioPharma plunges as deal for lead asset falls apart

DPRO

MTNB

WRIV

Press Releases

In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

Matinas BioPharma's LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Health Care

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Comments

Matinas BioPharma Hldgs

Vendite allo scoperto

Matinas BioPharma Hldgs (AMEX:MTNB) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO